IL272060A - Compositions containing cannabinoid analog conjugates and methods of use - Google Patents

Compositions containing cannabinoid analog conjugates and methods of use

Info

Publication number
IL272060A
IL272060A IL272060A IL27206020A IL272060A IL 272060 A IL272060 A IL 272060A IL 272060 A IL272060 A IL 272060A IL 27206020 A IL27206020 A IL 27206020A IL 272060 A IL272060 A IL 272060A
Authority
IL
Israel
Prior art keywords
methods
compositions containing
cannabinoid analog
analog conjugates
containing cannabinoid
Prior art date
Application number
IL272060A
Other languages
Hebrew (he)
Inventor
L Bryant Jerry Jr
J Yang David
Rauvolfova Jana
STRONG Tori
Original Assignee
Vyripharm Entpr Llc
L Bryant Jerry Jr
J Yang David
Rauvolfova Jana
STRONG Tori
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vyripharm Entpr Llc, L Bryant Jerry Jr, J Yang David, Rauvolfova Jana, STRONG Tori filed Critical Vyripharm Entpr Llc
Publication of IL272060A publication Critical patent/IL272060A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/0412—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K51/0421—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nuclear Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
IL272060A 2017-07-18 2020-01-15 Compositions containing cannabinoid analog conjugates and methods of use IL272060A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762533894P 2017-07-18 2017-07-18
PCT/US2018/042707 WO2019018536A1 (en) 2017-07-18 2018-07-18 Compositions containing cannabinoid analog conjugates and methods of use

Publications (1)

Publication Number Publication Date
IL272060A true IL272060A (en) 2020-03-31

Family

ID=65016693

Family Applications (1)

Application Number Title Priority Date Filing Date
IL272060A IL272060A (en) 2017-07-18 2020-01-15 Compositions containing cannabinoid analog conjugates and methods of use

Country Status (10)

Country Link
EP (1) EP3654971A4 (en)
JP (1) JP2020527589A (en)
KR (1) KR20200031663A (en)
CN (1) CN111065391A (en)
AU (1) AU2018302155B2 (en)
CA (1) CA3070538A1 (en)
EA (1) EA202090116A1 (en)
IL (1) IL272060A (en)
MX (1) MX2020000673A (en)
WO (1) WO2019018536A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3145109A1 (en) * 2019-06-24 2020-12-30 Diverse Biotech, Inc. Cannabinoid conjugate molecules
EP4045023A4 (en) * 2019-10-15 2023-09-13 Diverse Biotech, Inc. Conjugate molecules
CN112807301A (en) * 2020-12-30 2021-05-18 福建省中科生物股份有限公司 Application of Cannabicol extracted from hemp plant in preparing antitumor drug
US11554184B2 (en) 2021-03-26 2023-01-17 Vyripharm Enterprises, Inc. Synthetic cannabinoid combination therapy compositions and methods for personalized and targeted therapies including the treatment of infectious diseases
US20220305145A1 (en) * 2021-03-26 2022-09-29 Vyripharm Enterprises, Inc. Compositions and methods for diagnosing viral infections including covid-19 and for infection severity monitoring as well as targeted detection of cytokine storm
US20220305148A1 (en) * 2021-03-26 2022-09-29 Vyripharm Enterprises, Inc. Natural cannabinoid combination therapy compositions and methods for personalized and targeted therapies including the treatment of infectious diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007527389A (en) * 2003-06-30 2007-09-27 メルク　エンド　カムパニー　インコーポレーテッド Radioactive cannabinoid-1 receptor modulator
WO2007120153A1 (en) * 2006-04-19 2007-10-25 The Board Of Regents Of The University Of Texas System Compositions and methods for cellular imaging and therapy
US8367714B2 (en) * 2007-08-28 2013-02-05 Vanderbilt University Cannabinoid receptor targeted agent
US20120288442A1 (en) * 2011-05-11 2012-11-15 Atomic Energy Council-Institute Of Nuclear Energy Research Nuclear Imaging Method Using Molecular Target Detection Agent for Liver Fibrosis
EP2992880A1 (en) * 2014-09-04 2016-03-09 Fundació Institut de Recerca de l'Hospital de la Santa Creu l Sant Pau Use of heme oxygenase 1 inducers and cannabinoid 2 receptor or delta-opioid receptor agonists in inflammatory pain
GB201417067D0 (en) * 2014-09-26 2014-11-12 South African Nuclear Energy Radiopharmaceutical conjugate

Also Published As

Publication number Publication date
MX2020000673A (en) 2020-07-29
AU2018302155A1 (en) 2020-02-06
JP2020527589A (en) 2020-09-10
CN111065391A (en) 2020-04-24
WO2019018536A1 (en) 2019-01-24
AU2018302155B2 (en) 2022-09-15
EP3654971A1 (en) 2020-05-27
KR20200031663A (en) 2020-03-24
CA3070538A1 (en) 2019-01-24
EA202090116A1 (en) 2020-05-14
EP3654971A4 (en) 2021-04-21

Similar Documents

Publication Publication Date Title
GB2582482B (en) CASZ compositions and methods of use
GB2582100B (en) CAS12C Compositions and methods of use
EP3595653A4 (en) Compositions of plinabulin and use thereof
EP3576782A4 (en) Construct-peptide compositions and methods of use thereof
IL268970A (en) Novel compositions and methods
IL272060A (en) Compositions containing cannabinoid analog conjugates and methods of use
IL271275A (en) Compositions comprising curons and uses thereof
ZA201906169B (en) Synthekine compositions and methods of use
EP3691677A4 (en) Saccharide-polypeptide conjugate compositions and methods of use thereof
GB202201861D0 (en) Novel methods and compositions
ZA202100780B (en) Bismuth-thiol compositions and methods of use
IL276135A (en) Compositions and methods of use
IL274166A (en) Cannabinoid compositions and methods of use therof
IL275739A (en) Compositions for cryopreservation and methods of use thereof
EP3402443A4 (en) Devices and compositions and methods of use thereof
IL272834A (en) Amantadine compositions, preparations thereof, and methods of use
IL291730A (en) Protein-macromolecule conjugates and methods of use thereof
PL3638278T3 (en) Neuroprotective compositions and their use
IL274433A (en) Fulvestrant formulations and methods of their use
ZA202000502B (en) Cosmetic compositions and methods of use
EP3635324A4 (en) Inverse-freezing compositions and use thereof
ZA202007107B (en) Compositions comprising pcsk9-binding molecules and methods of use
IL274563A (en) Methods of using and compositions containing dulaglutide
IL261794A (en) Compositions and methods of their use
IL273904A (en) Pharmaceutical resinate compositions and methods of making and using thereof